Home/Filings/4/0001209191-18-046773
4//SEC Filing

Young Jeffrey E 4

Accession 0001209191-18-046773

CIK 0000821995other

Filed

Aug 14, 8:00 PM ET

Accepted

Aug 15, 4:16 PM ET

Size

10.6 KB

Accession

0001209191-18-046773

Insider Transaction Report

Form 4
Period: 2018-08-14
Young Jeffrey E
Chief Financial Officer
Transactions
  • Disposition to Issuer

    Common Stock

    2018-08-14$11.50/sh30,413$349,7500 total
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2018-08-1440,0000 total
    Exercise: $7.90Exp: 2025-02-09Common Stock (40,000 underlying)
  • Disposition to Issuer

    Nonqualified Stock Option (right to buy)

    2018-08-14170,0000 total
    Exercise: $5.60Exp: 2024-01-03Common Stock (170,000 underlying)
Footnotes (3)
  • [F1]Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement") among Catalent Pharma Solutions, Inc., Catalent Boston, Inc. and Juniper Pharmaceuticals Inc. (the "Issuer") dated as of July 2, 2018. At the effective time of the merger (the "Effective Time") as contemplated in the Merger Agreement, each share of outstanding Issuer common stock (other than appraisal shares and certain other shares), and each outstanding and unexercised Issuer stock option (whether vested or unvested) and each outstanding unvested restricted stock unit, immediately prior to the Effective Time were cancelled in exchange for $11.50 per share, net in cash, without interest, less any applicable taxes and applicable exercise price for the stock option (the "Offer Price").
  • [F2]Includes 27,150 restricted stock units that did not vest prior to the Effective Time of the merger. Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unvested 27,150 restricted stock units was cancelled in exchange for the Offer Price.
  • [F3]Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unexercised Issuer stock options (whether vested or unvested) was cancelled in exchange for cash equal to the product of (i) the excess of the Offer Price over the exercise price of the option and (ii) shares issuable upon exercise of the outstanding stock options.

Issuer

JUNIPER PHARMACEUTICALS INC

CIK 0000821995

Entity typeother

Related Parties

1
  • filerCIK 0001367556

Filing Metadata

Form type
4
Filed
Aug 14, 8:00 PM ET
Accepted
Aug 15, 4:16 PM ET
Size
10.6 KB